Luting Cements for Prefabricated Zirconia Crown Retention in Primary Anterior Teeth in Children
Comparison of Self-Adhesive Resin, Conventional Glass Ionomer, and Bioactive Resin-Modified Glass Ionomer Cements for Prefabricated Zirconia Crown Retention in Primary Anterior Teeth: A Randomized Controlled Trial
The goal of this clinical trial is to compare the long-term clinical performance of three different luting cements used to bond prefabricated zirconia crowns (PZCs) on primary front teeth in young children. The trial will determine whether any single cement offers superior retention, gum health, or marginal sealing compared to the others over a 3-year period.
Main Questions:
The study aims to answer the following:
Are conventional glass ionomer cement (GIC), bioactive resin-modified glass ionomer cement (BioCem™), and self-adhesive resin cement (SARC) equivalent in retaining prefabricated zirconia crowns on primary incisors over 36 months? Do these cements differ in their effect on gingival health, plaque accumulation, or marginal discoloration around the cemented crown?
Comparison:
Researchers will compare three parallel groups of children whose primary incisors are restored with identical prefabricated zirconia crowns but cemented with one of the three different luting cements.
Participants will: Receive a clinical and radiographic dental examination at screening. Undergo placement of one or more prefabricated zirconia crowns on primary anterior teeth using their randomly assigned cement. Return to the clinic for blinded follow-up evaluations at 12, 24, and 36 months for assessment of crown retention, gingival health, plaque, and marginal staining.
調査の概要
状態
詳細な説明
This prospective, parallel-group, three-arm, randomized controlled trial evaluates the long-term clinical performance of three commercially available luting cements when used to bond prefabricated zirconia crowns (PZCs) on primary anterior teeth in pediatric patients. Although PZCs are increasingly preferred over stainless steel crowns for anterior restorations due to their superior esthetics and biocompatibility, their retention relies entirely on the luting cement because of their passive fit and conservative preparation design. Comparative clinical evidence on cement performance in this specific anatomical and functional context remains limited.
Trial Design:
The trial is conducted at the Pediatric Dental Clinic of Qassim University, Riyadh, Saudi Arabia. Eligible children aged 2 to 7 years requiring full-coverage restoration of one or more primary incisors are randomized in a 1:1:1 ratio to one of three cement groups using a computer-generated randomization sequence. Allocation labels are reshuffled after each assignment to preserve equal group sizes. An independent outcome assessor is blinded to group allocation throughout the trial, and standardized cheek retractors are used to mask cement margins during evaluations. Operators cannot be blinded due to material-specific application protocols.
Intervention Protocols:
Tooth preparation follows standardized anterior-specific minimal reduction principles (1.0-1.5 mm incisal, 0.5-0.8 mm uniform labial, feather-edge proximal margins) under rubber dam isolation. NuSmile® prefabricated zirconia crowns are used for all participants. Cement application follows manufacturer instructions for each group:
Group 1 (GIC): Fuji IX GP Extra (GC America) - tooth conditioned with 20% polyacrylic acid for 20 seconds, rinsed, gently air-dried; cement hand-mixed, loaded into crown, seated under finger pressure for 3 minutes.
Group 2 (BioCem™): BioCem™ Universal BioActive Cement (NuSmile®) - tooth cleaned with pumice and water, rinsed, dried; cement auto-mixed into crown, seated, briefly light-cured (2-3 s) for excess removal, then fully light-cured 20 s per surface.
Group 3 (SARC): RelyX™ Universal Resin Cement (3M) - tooth cleaned with pumice and water, rinsed, dried; cement loaded, crown seated, tack-cured 2-3 s, excess removed, full light-curing 20 s per surface.
All crowns are placed by a single calibrated pediatric dentist. Post-cementation periapical radiographs verify marginal integrity. Parents receive standardized oral hygiene instructions and a 7-day course of 0.12% chlorhexidine mouthwash.
Follow-Up and Safety:
Clinical evaluations occur at baseline, 12, 24, and 36 months. Retention is assessed by visual/tactile examination with a sharp explorer and LED transillumination (DEXIS CariVu®). Failed crowns are recemented and excluded from subsequent analyses. Adverse events including soft-tissue irritation, crown fracture, debonding, and aspiration risk are continuously recorded.
Statistical Methodology:
Sample size was calculated using G*Power 3.1.9.7 assuming a medium effect size (f = 0.25) for ANOVA, 90% power, and α = 0.05, yielding 28 participants per group; this was inflated to 40 per group (total 120) to accommodate an anticipated 30% attrition over 36 months. The primary retention outcome will be analyzed by Kaplan-Meier survival analysis with between-group comparison using the log-rank test, supplemented by Fisher's exact test for proportional retention and Cox proportional hazards regression for hazard ratios. Gingival Index and Plaque Index will be compared between groups by one-way ANOVA and within groups by repeated-measures ANOVA. Margin discoloration distribution will be compared by chi-square (with Cramér's V as effect size) and within-group transitions by McNemar's test. Significance is set at p < 0.05. Analyses will follow an intention-to-treat principle, with per-protocol sensitivity analyses.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:MURAD ALRASHIDI, BDS, MSC
- 電話番号:+966 55 302 2773
- メール:MU.ALRASHIDI@qu.edu.sa
研究場所
-
-
Al-Qassim Region
-
Buraidah、Al-Qassim Region、サウジアラビア、52571
- Qassim University
-
コンタクト:
- MURAD ALRASHIDI
- 電話番号:+966 55 302 2773
- メール:MU.ALRASHIDI@qu.edu.sa
-
-
参加基準
適格基準
就学可能な年齢
- 子
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Healthy children aged 2 to 7 years
- One or more primary maxillary or mandibular incisors requiring full-coverage restoration due to caries or trauma
- Adequate remaining tooth structure following preparation, defined as greater than 50% of the clinical crown
- Parent or legal guardian able and willing to provide written informed consent and to commit to the 36-month follow-up schedule
Exclusion Criteria:
- Active periodontal disease at the index tooth, defined as a Löe Gingival Index score of 2 or higher
- Parafunctional habits such as bruxism, severe thumb-sucking, or tongue-thrust documented at screening
- Known allergy or hypersensitivity to zirconia, resin, glass ionomer, or any component of the assigned cement
- Inconsistent oral hygiene, defined as less than twice-daily toothbrushing per parental report
- Systemic disease affecting bone metabolism, tooth development, or wound healing
- Current participation in another interventional dental clinical trial
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Glass Ionomer Cement (GIC) Group
Glass Ionomer Cement (GIC) Group: Participants receive a NuSmile® prefabricated zirconia crown cemented with conventional glass ionomer cement (Fuji IX GP Extra, GC America) following a standardized polyacrylic-acid-conditioning protocol.
|
Cementation with Fuji IX GP Extra Glass Ionomer Cement Hand-mixed conventional glass ionomer luting cement applied per manufacturer protocol; crown seated under finger pressure for 3 minutes; excess removed after initial set.
|
|
実験的:Bioactive Resin-Modified Glass Ionomer Cement (BioCem™) Group
Bioactive Resin-Modified Glass Ionomer Cement (BioCem™) Group: Participants receive an identical NuSmile® prefabricated zirconia crown cemented with BioCem™ Universal BioActive Cement (NuSmile®, Houston, TX, USA).
|
Cementation with BioCem™ Universal BioActive Cement Auto-mixed bioactive resin-modified luting cement applied per manufacturer protocol; brief tack-cure to facilitate excess removal followed by full light-curing for 20 seconds per surface.
|
|
実験的:Self-Adhesive Resin Cement (SARC) Group
Self-Adhesive Resin Cement (SARC) Group: Participants receive an identical NuSmile® prefabricated zirconia crown cemented with RelyX™ Universal Resin Cement (3M).
|
Cementation with RelyX™ Universal Resin Cement Self-adhesive dual-cure resin luting cement applied per manufacturer protocol; tack-cured for 2-3 seconds for excess removal, followed by full light-curing for 20 seconds per surface.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Crown Retention (Survival)
時間枠:Baseline, 12, 24, and 36 months post-cementation
|
The primary outcome is the cumulative retention of prefabricated zirconia crowns over a 36-month follow-up period.
Retention is assessed by a single blinded examiner at each scheduled visit using two complementary methods: (a) visual/tactile inspection with a sharp dental explorer applied circumferentially along the crown margin to detect dislodgement, mobility, or marginal gap; and (b) LED transillumination using the DEXIS CariVu® system to detect cracks, debonding, or marginal microleakage.
A crown is classified as "failed" (debonded) if any complete loss of cement seal, dislodgement, or detectable marginal gap is observed.
Retention is reported as the proportion of crowns surviving at each time point and as the time-to-failure for survival analysis.
Higher retention proportions and longer survival times indicate better clinical performance.
|
Baseline, 12, 24, and 36 months post-cementation
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Plaque Accumulation Measured by the Silness & Löe Plaque Index (1964)
時間枠:Baseline, 12, 24, and 36 months post-cementation
|
Plaque accumulation at the gingival margin of each cemented crown is assessed using the Silness & Löe Plaque Index.
The same four sites per tooth (mesial, distal, buccal, lingual) are scored by a blinded examiner on a 4-point ordinal scale: 0 = no plaque; 1 = a film of plaque adhering to the free gingival margin, recognizable only by running a probe across the surface; 2 = moderate accumulation of soft deposits visible to the naked eye; 3 = abundance of soft matter.
A mean PI score is calculated per tooth and per participant; the participant-level mean ranges from a minimum of 0 to a maximum of 3, with higher scores indicating greater plaque accumulation.
|
Baseline, 12, 24, and 36 months post-cementation
|
|
Gingival Health Measured by the Löe Gingival Index (1967)
時間枠:Baseline, 12, 24, and 36 months post-cementation
|
Gingival inflammation around each cemented crown is assessed at baseline and at every follow-up visit using the Löe Gingival Index (1967).
A single blinded examiner scores four gingival sites per tooth (mesial, distal, buccal, and lingual) on a 4-point ordinal scale: 0 = no clinical inflammation (normal gingiva); 1 = mild inflammation (slight color change, slight edema, no bleeding on probing); 2 = moderate inflammation (redness, edema, glazing, bleeding on probing); 3 = severe inflammation (marked redness and edema, ulceration, tendency to spontaneous bleeding).
A mean GI score is calculated per tooth and per participant; the participant-level mean therefore ranges from a minimum of 0 to a maximum of 3, with higher scores indicating worse gingival health.
|
Baseline, 12, 24, and 36 months post-cementation
|
|
Marginal Discoloration Measured by the Modified United States Public Health Service (USPHS) Criteria
時間枠:Baseline (immediately post-cementation), 12, 24, and 36 months
|
Discoloration at the crown-tooth interface is evaluated under standardized LED operatory lighting (1,000-1,400 lux) without magnification using the modified USPHS criteria, supplemented by high-resolution intraoral photography with cross-polarized filters.
Each crown is assigned one of four ordinal ratings: Alpha (A) = no visible discoloration (best outcome); Bravo (B) = slight discoloration confined to the margin, not penetrating internally; Charlie (C) = obvious discoloration penetrating along the margin; Delta (D) = severe discoloration with secondary caries or restoration failure (worst outcome).
The outcome is reported as the proportion of crowns in each category at each time point, with a higher proportion of Alpha ratings indicating better marginal integrity.
|
Baseline (immediately post-cementation), 12, 24, and 36 months
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence and Severity of Adverse Events
時間枠:Continuously, from cementation through 36 months
|
The frequency, type, and severity of all adverse events occurring during the 36-month follow-up will be recorded for each arm.
Events of interest include crown debonding, crown fracture, soft-tissue irritation or ulceration adjacent to the crown margin, allergic reaction to cement components, secondary caries, and pulpal complications.
Severity will be classified using a three-tier framework adapted from the Common Terminology Criteria for Adverse Events (CTCAE) approach: Mild (Grade 1) - no intervention required; Moderate (Grade 2) - non-urgent intervention required (e.g., recementation at a scheduled visit); Severe (Grade 3) - urgent intervention, crown replacement, or treatment of secondary pathology required.
The primary safety endpoint is the incidence rate (events per participant per year of follow-up) in each arm.
|
Continuously, from cementation through 36 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:MURAD ALRASHIDI, BDS, MSC、Qassim University
出版物と役立つリンク
一般刊行物
- Leuciuc FV, Petrariu I, Pricop G, Rohozneanu DM, Popovici IM. Toward an Anthropometric Pattern in Elite Male Handball. Int J Environ Res Public Health. 2022 Feb 28;19(5):2839. doi: 10.3390/ijerph19052839.
- Wu M, Liu X, Li Z, Huang X, Guo H, Guo X, Yang X, Li B, Xuan K, Jin Y. SHED aggregate exosomes shuttled miR-26a promote angiogenesis in pulp regeneration via TGF-beta/SMAD2/3 signalling. Cell Prolif. 2021 Jul;54(7):e13074. doi: 10.1111/cpr.13074. Epub 2021 Jun 7.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- 26-19-6
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD 共有時間枠
IPD 共有アクセス基準
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。